News | May 16, 2011

Frost & Sullivan Awards GE ‘Price Performance Value’ Leadership in PET Award

May 16, 2011 — GE Healthcare today received the Price Performance Value Leadership Award in PET (positron emission tomography) for North America 2011 from global research organization Frost & Sullivan.

According to Frost & Sullivan, the Price Performance Value Leadership Award is a prestigious recognition of GE Healthcare’s accomplishments in PET. Based on Frost & Sullivan’s analysis of the latest value-based systems currently being offering by PET/CT manufacturers, GE Healthcare’s Optima PET/CT 560 was found to offer a higher price performance value than any other system on the market.

First to the market with PET/CT in 2001, GE Healthcare has built upon its excellence in PET/CT with the Optima PET/CT 560, an innovative scanner designed to address the demands of today’s healthcare environment. Combining superb image quality, high productivity and a patient friendly experience, the Optima PET/CT 560 can continuously deliver ongoing value over time. The system offers efficiency and investment protection with the capability to grow with the future needs of the clinical practice. From the uninterrupted full head to toe exam to the remarkable dose reduction features, the Optima PET/CT 560 was designed to help physicians put patients’ needs first. It includes advanced VUE Point HD intelligent 3-D iterative reconstruction technique to enhance resolution for uncompromised image quality that can help enable clinicians to confidently detect small lesions and increase quantitative accuracy.

According to Frost & Sullivan, despite growing evidence pointing to its superior diagnostic capabilities in many applications within oncology and cardiology, PET/CT’s higher costs have been a deterrent to widespread adoption of this technology since its commercial introduction in 2001. Frost & Sullivan notes that the recent downturn in the U.S. economy and uncertainties surrounding healthcare reform further exasperated this challenge, as these circumstances intensified demand in the market for the more affordable imaging equipment that provides adequate performance in clinically relevant applications. Frost & Sullivan also notes the significant cost-barrier in PET/CT has prompted manufacturers of this technology to become more focused on developing systems that provide the highest performance at the lowest price point possible.

For more information: www.gehealthcare.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init